The treatment landscape for hemophilia A and B is expanding with strategies and therapies to optimize efficacy, provide durable hemostasis restoration, and improve safety. These contemporary approaches to care have also led to new pathways and assays for clinical and …
More than 80% of patients with ulcerative colitis (UC), including those receiving treatment, experience bowel urgency. This symptom dramatically impacts patient quality of life (QoL) and can lead to depression, social isolation, disruption with work, interference with relationships, and fatigue. …
Interleukin (IL)-23 has been identified as a main driver of inflammation in inflammatory bowel disease (IBD) and has been identified as a target for highly effective advanced therapies. While all agents in the anti-IL-23 class of monoclonal antibodies (mABs) neutralize …
Due to the rising prevalence and significant burden of Alzheimer’s disease there is a critical need for continuing education aimed at bridging existing gaps in clinician knowledge, competence, and performance concerning novel and emerging amyloid-targeting therapies (ATTs), especially in the …
Racism has historically, systemically, and continuously developed and fueled discriminatory practices and rhetoric against racial and ethnic underserved individuals in the United States. Those practices remain embedded in society and institutions, including the healthcare system. Given the long-standing history and …
Data from recent clinical trials for first-line combination options using immunotherapies for ovarian cancer (OC) can be challenging for clinicians with no experience selecting patients for combinatorial treatment approaches or using combination therapies for their patients. During this podcast, Drs. …
The 2016 Guideline for Prescribing Opioids for Chronic Pain, produced by the Centers for Disease Control and Prevention (CDC), effectively changed opioid prescribing with a decrease in the number of high-dose opioid prescriptions. Since then, however, there has been misapplication …
The treatment landscape for psoriasis (PsO) and psoriatic arthritis (PsA) is evolving, yet many novel approaches have limitations. Several Janus kinase inhibitors (JAKis) have indications for only one of the two conditions; others carry black box warnings from the U.S. …
Psoriatic arthritis (PsA) diagnosis and management have been directed by three main sets of guidelines: the American College of Rheumatology (ACR) guidelines, the European Alliance of Associations for Rheumatology (EULAR) guidelines, and the Group for Research and Assessment of Psoriasis …